EyeSol®, Novaliq’s unique and proprietary water-free technology, opens completely new and intriguing opportunities to target key drivers of the disease and have constantly demonstrated significant improvement in sign and symptoms of dry eye in clinical trials.
NovaTears® is the first water-free eye drop based on EyeSol® developed for the treatment of dry eye. Novatears® is CE certified since 2014 and successfully commercialized in Australia/New Zealand and in Europe by our partners.
NovaTears® is clinically validated by significant improvement in signs and symptoms in evaporative dry eye disease and MGD patients (4 clinical trials).
NovaTears®+Omega-3 eye-drops is a line extension of Novaliq’s existing CE-marked product NovaTears® containing 0,2% Omega-3 fatty acids.
The clear, multi-dose solution is stable at ambient temperatures and intended for use as an ocular lubricant in conditions involving instability of the tear film leading to dry eye syndrome
Our water-free technology, opens completely new and intriguing opportunities to cure, relief and prevent diseases in various indications.
Approved CE products: Novatears®, Novatears®+Omega-3
Novaliq has a rich pre-clinical pipeline covering a wide range of topical therapies in both, Ophthalmology and Dermatology.
For our products we only use highly pure substances and raw materials from qualified manufacturers. We have extensively tested and proven their safety, efficacy and tolerability in close cooperation with the regulatory authorities in Europe and USA, both preclinically and clinically.